Here, we sought to evaluate the effect of combining STAT3 inhibitor LLL12B and cisplatin, which is a platinum-based chemotherapeutic agent used in frontline treatment regimens for brain tumors of childhood including medulloblastoma5. The gene discussed is STAT3; the disease is brain neoplasm.